BMS's Opdivo more than doubles 1-year survival in lung cancer
This article was originally published in Scrip
Enthusiasm for Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) grew on 30 October when the company revealed Phase II data that showed one-year survival was more than double historical results in third-line treatment of squamous cell non-small cell lung cancer (NSCLC) patients.
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.